Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Study:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Rationale:

n/a

Purpose:

This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of CMX001 administered once weekly for up to 11 weeks. Dosing will be initiated immediately following engraftment (between Days 14-30 post-transplant) to prevent/control CMV infection or prevent disease in R+ allogeneic stem cell transplant recipients.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cytomegalovirus Infection Drug: CMX001
Drug: Placebo
Phase 2

Verified by Chimerix January, 2012

Sponsored by: Chimerix
Information provided by: Chimerix
ClinicalTrials.gov identifier: NCT00942305

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

The Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site